Holen Sie sich die Stockscreener-App
1.64
0.91%
-0.02
Protalix BioTherapeutics Inc. Aktie (PLX) Neueste Nachrichten
Protalix signals $100M+ Elfabrio royalties by 2030 as Phase II PRX-115 trial advances - MSN
Using data tools to time your Protalix BioTherapeutics Inc. exit2025 Investor Takeaways & Reliable Volume Spike Alerts - Newser
Forecasting Protalix BioTherapeutics Inc. price range with options dataJuly 2025 Analyst Calls & Verified Stock Trade Ideas - Newser
How Protalix BioTherapeutics Inc. stock reacts to Fed policy changesSell Signal & Growth Focused Entry Reports - Newser
Can machine learning forecast Protalix BioTherapeutics Inc. recoveryTrade Exit Summary & Long Hold Capital Preservation Tips - Newser
Why Protalix BioTherapeutics Inc. stock attracts strong analyst attentionMarket Sentiment Summary & Reliable Entry Point Alerts - Newser
Key metrics from Protalix BioTherapeutics Inc.’s quarterly dataMarket Volume Report & Free Community Consensus Stock Picks - Newser
What analysts say about Protalix BioTherapeutics Inc. stockJuly 2025 Price Swings & Advanced Swing Trade Entry Alerts - sundaytimes.kr
Can Protalix BioTherapeutics Inc. deliver consistent EPS growthDividend Hike & Free Reliable Trade Execution Plans - thegnnews.com
What’s the recovery path for long term holders of Protalix BioTherapeutics Inc.Market Growth Review & Community Consensus Trade Signals - Newser
Protalix BioTherapeutics Experiences Strong Revenue Growth, Strategic Partnerships Drive Success - AInvest
Protalix BioTherapeutics Announces Q2 2025 Results, New CFO to Take Over. - AInvest
PLX: New CFO to Take the Reins - Yahoo Finance
When is the best time to exit Protalix BioTherapeutics Inc.IPO Watch & Technical Entry and Exit Tips - Newser
The Psychology of Protalix BioTherapeutics Inc Inc. (PLX) Price Performance: Understanding Market Sentiment - investchronicle.com
Protalix BioTherapeutics, Inc. (AMEX:PLX) Q2 2025 Earnings Call Transcript - Insider Monkey
Protalix BioTherapeutics Inc (PLX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Protalix BioTherapeutics Reports Strong Q2 2025 Results - TipRanks
Protalix Revenue Jumps 16 Percent in Q2 - AOL.com
Protalix BioTherapeutics Inc. stock momentum explainedMarket Activity Report & Weekly Chart Analysis and Guides - Newser
Protalix BioTherapeutics shares rise 2.65% after-hours after reporting a 50% increase in revenues for the first half of 2025. - AInvest
Protalix BioTherapeutics Q2 2025 Earnings Call Transcript: A Detailed Review of Financial Results and Business Update - AInvest
Protalix's Q2 2025: Unpacking Contradictions in Fabry Disease Market Strategy and Clinical Development - AInvest
Transcript : Protalix BioTherapeutics, Inc., Q2 2025 Earnings Call, Aug 14, 2025 - MarketScreener
Earnings call transcript: Protalix Q2 2025 misses EPS, beats revenue expectations - Investing.com Nigeria
Earnings call transcript: Protalix Q2 2025 misses EPS, beats revenue expectations By Investing.com - Investing.com South Africa
Protalix BioTherapeutics lifts revenue on strong Elfabrio demand - Proactive financial news
Protalix BioTherapeutics Reports Second Quarter 2025 Financial and Business Results - PR Newswire
Protalix BioTherapeutics to Announce Second Quarter 2025 Financial and Business Results on August 14, 2025 - PR Newswire
Chart based analysis of Protalix BioTherapeutics Inc. trendsWeekly Gains Report & Weekly Return Optimization Alerts - Newser
Fibonacci Retracement Aligns with Support in Protalix BioTherapeutics Inc.2025 Major Catalysts & Risk Adjusted Buy and Sell Alerts - beatles.ru
Why Protalix BioTherapeutics Inc. is moving today2025 Macro Impact & Breakout Confirmation Trade Signals - Newser
Director’s Bold Move: Major Investment in Protalix Stock - TipRanks
Protalix BioTherapeutics Director Schwartz Aharon Buys 129000 Shares at $1.6/Share. - AInvest
Will Protalix BioTherapeutics Inc. stock go up in YEARHigh Growth Alert System - newsyoung.net
How Protalix BioTherapeutics Inc. stock performs during market volatilitySecure Buy Strategy Based on Risk Parameters - Newser
Reviewing Protalix BioTherapeutics (NYSE:PLX) & Cortexyme (NASDAQ:CRTX) - Defense World
Exit strategy if you’re trapped in Protalix BioTherapeutics Inc.Free Weekly Setup With 3x Return Potential - Newser
Key External Factors That Drive Protalix BioTherapeutics Inc. Stock Price MovementsMinimal Risk Growth Investment Opportunity Analysis - Newser
Top chart patterns to watch in Protalix BioTherapeutics Inc.Short-Term Upside Breakout Forecast System - Newser
Quantitative breakdown of Protalix BioTherapeutics Inc. recent moveFree Real Profit Trade Plan Suggestions - Newser
Financial Contrast: PharmaCyte Biotech (OTCMKTS:PMCBD) and Protalix BioTherapeutics (NYSE:PLX) - Defense World
Protalix BioTherapeutics Earnings: Key Q2 2025 Financial Results and Business Updates Coming August 14 - Stock Titan
Do the Shorts Know Something You Don't? - AOL.com
Are Bears Losing Grip on Protalix BioTherapeutics Inc.Real-Time Analysis With Entry Targets In Progress - beatles.ru
What are the latest earnings results for Protalix BioTherapeutics Inc.Capitalize on emerging market sectors - Jammu Links News
How strong is Protalix BioTherapeutics Inc. company’s balance sheetGet real-time updates on market trends - Jammu Links News
Should I hold or sell Protalix BioTherapeutics Inc. stock in 2025Free Consultation - Jammu Links News
What is Protalix BioTherapeutics Inc. company’s growth strategyAchieve remarkable returns with smart investing - Jammu Links News
How does Protalix BioTherapeutics Inc. compare to its industry peersGet daily updates on promising stocks - Jammu Links News
What makes Protalix BioTherapeutics Inc. stock price move sharplyAchieve consistent double-digit returns - Jammu Links News
What drives Protalix BioTherapeutics Inc. stock priceDynamic profit expansion - Jammu Links News
When is Protalix BioTherapeutics Inc. stock expected to show significant growthGet timely alerts on market movers - Jammu Links News
0.39%
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):